New Study On Cannabis Represents an Interesting New Profile Of CBD That Could Lead To Its Introduction In The Clinical Management of MS

“Multiple Sclerosis (MS) is a global concern disease leading to a progressive, chronic and demyelinating condition, affecting the central nervous system (CNS). The pathology has an inflammatory/autoimmune origin; nevertheless, neuronal cell death mechanisms are not to be underestimated.”
The recent study “Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis” from the Experimental Neurology Laboratory, IRCCS Centre Neurolesi “Bonino-Pulejo”, Messina, Italy was designed to test the effects of intraperitoneal administration of cannabidiol (CBD), the main non-psychotropic cannabinoid of Cannabis sativa (CS), in an experimental model of MS. The aim was to evaluate the capability of CBD administration to thwart the cascade of mediators involved in MS-induced apoptosis. We learn from this study that “Most of therapeutic properties of CS are currently ascribed to the psychotropic effects of phenylterpenoid delta-9 tetrahydrocannabinol.” and “alone, purified CBD possesses an anti-apoptotic power against the neurodegenerative processes underlying MS development. This represents an interesting new profile of CBD that could lead to its introduction in the clinical management of MS.”

To cite this article

S. Giacoppo, T. Soundara Rajan, M. Galuppo, F. Pollastro, G. Grassi, P. Bramanti, E. Mazzon
Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis
Eur Rev Med Pharmacol Sci 
Year: 2015
Vol. 19 – N. 24
Pages: 4906-4919
 
http://nyp.org/services/neuroscience/multiple-sclerosis.html